Chemokine Therapeutics Corp. Withdraws Registration Statement, Reduction in Workforce 65%, Reduced salaries, CEO Resigned

VANCOUVER, BRITISH COLUMBIA--(Marketwire - December 04, 2007) - Chemokine Therapeutics Corp. (the "Company") (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announced that the Company has withdrawn the registration statement relating to the public offering, announced on May 30, 2007, due to market conditions. The Company is currently evaluating financing alternatives to fund ongoing activities.